Vimarsana
Biggest News Aggregation in the World

Page 5 - Neuraxis Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Neuraxis Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Neuraxis Inc Today - Breaking & Trending Today

NeurAxis Reports Third Quarter 2023 Financial Results - Vimarsana News

NeurAxis Reports Third Quarter 2023 Financial Results

CARMEL, Ind., Nov. 20, 2023 -- NeurAxis, Inc. , a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults,...

NeurAxis Announces CareFirst BCBS Policy Coverage - Vimarsana News

NeurAxis Announces CareFirst BCBS Policy Coverage

CARMEL, Ind., Nov. 15, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in

NeurAxis PENFS IB-Stim Technology: A Drug-Free, Non-Invasive Way To Effectively Treat Pediatric Functional Abdominal Pain Associated With IBS ($NRXS) -October 04, 2023 at 05:09 am EDT - Vimarsana News

NeurAxis PENFS IB-Stim Technology: A Drug-Free, Non-Invasive Way To Effectively Treat Pediatric Functional Abdominal Pain Associated With IBS ($NRXS) -October 04, 2023 at 05:09 am EDT

NeurAxis Inc. proves that a smallcap biotech can deliver best-in-market care. That's more than great news for NRXS from a revenue perspective and for its patients from a treatment point of view. It...

NeurAxis Stock Rallies 26% as Adoption of Drug-Free IB-Stim Technology to Treat Pediatric FAP/IBS Gains Momentum ($NRXS) - Vimarsana News

NeurAxis Stock Rallies 26% as Adoption of Drug-Free IB-Stim Technology to Treat Pediatric FAP/IBS Gains Momentum ($NRXS)

NeurAxis Inc. stock is in rally mode, jumping over 26% since last week. Despite this significant increase, investors following this innovative biotech anticipate further growth. That optimism is...

NeurAxis Stock Has 236% Upside Says GSCR Analyst, Fueled By Drug-Free IB-Stim Technology To Treat Pediatric Irritable Bowel Syndrome ($NRXS) - Vimarsana News

NeurAxis Stock Has 236% Upside Says GSCR Analyst, Fueled By Drug-Free IB-Stim Technology To Treat Pediatric Irritable Bowel Syndrome ($NRXS)

According to an analyst at Goldman Smallcap Research, NeurAxis Inc. shares at current levels present a compelling investment opportunity. In fact, he models for a 12-month price target of $14 a...